All stocks / ELTP
ELITE PHARMACEUTICALS INC /NV/ ELTP
Elite Pharmaceuticals INC /nv/ (ELTP): no warning signs from our rules in the last 12 months and the latest annual figures in plain language. Each fact links to its SEC filing.
Market listing
- Full name
- ELITE PHARMACEUTICALS INC
- Market tier
- OTCQB
- Trading status
- Active
- Last trade
- Nov 16
- Website
- www.elitepharma.com
News headlines
The financial report, and what it means
Annual figures to 2026-03-31- Revenue
- $148,870,119
- Net income
- $44,872,686
It earned more than it spent
SteadyAfter all costs, the company kept $44.9 million as profit in the year.
- Cash and cash equivalents
- $29,797,800
- Net cash from operating activities
- $23,748,094
The business brings in cash
SteadyDay-to-day business added $23.7 million in cash over the year. It had $29.8 million in the bank.
- Total assets
- $138,289,840
- Total liabilities
- $39,406,865
It owns more than it owes
SteadyEverything the company owns adds up to $138.3 million. Its debts and unpaid bills add up to $39.4 million. That is about $0.28 owed for every $1 owned.
What this adds up to
0 of 3 checks show strain. These are facts from the company's own reports, not a recommendation.
Signals
Estimated float about 1,068,204,220 shares as of 2026-11-12: 1,077,569,775 outstanding minus 9,365,555 held by 2 reporting insider(s).
Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record
Shares outstanding
Source: SEC filingsPrice chart
Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets
Recent filings
Common questions about ELTP
Does ELTP file reports with the SEC?
Yes. Elite Pharmaceuticals INC /nv/ files with the SEC under company number 0001053369. The most recent filing we hold is a 8-K dated 2026-11-12.
Source recordHow many ELTP shares are outstanding?
1,077,569,775 shares as of 2026-11-12, as reported to the SEC.
Source recordHas ELTP filed reports late?
We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.
Who runs Elite Pharmaceuticals INC /nv/?
Officers named in its insider filings: Douglas Plassche (EVP Operations).
Source recordIs Elite Pharmaceuticals INC /nv/ making money?
After all costs, the company kept $44.9 million as profit in the year. (Annual figures to 2026-03-31. Facts from the company's own report, not a recommendation.)
Source record